Citigroup Upgrades Ionis Pharmaceuticals to Buy, Raises Price Target to $60
Portfolio Pulse from richadhand@benzinga.com
Citigroup analyst David Lebowitz has upgraded Ionis Pharmaceuticals (NASDAQ:IONS) from Neutral to Buy and raised the price target from $36 to $60.
July 31, 2023 | 9:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals has been upgraded from Neutral to Buy by Citigroup, with a raised price target from $36 to $60.
The upgrade from Neutral to Buy by Citigroup indicates a positive outlook for Ionis Pharmaceuticals. The raised price target from $36 to $60 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100